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1. Introduction  
Enzymes are catalytic protein molecules performing specific functions in their native form. 
Native structure is one of basic conditions for normal function of proteins including 
enzymes. Catalytic activity of enzyme may be decreased by both non-covalent modulation 
by true inhibitors and covalent modifications by metabolites in the body or natural 
products. One example of such modulation is non-enzymatic glycation of proteins by 
sugars.   
Enzymes are very good models for studies of protein interactions with other molecules, 
including sugars (e.g., Arai et al., 1987; Dolhofer & Wieland, 1978; Okada et al., 1994; Okada 
et al., 1997; Sakurai et al., 1987). Advantage of these studies is the fact that enzyme 
interactions may be investigated not only by common methods of studies of protein 
properties like changes in spectral characteristics, molecular weight, charge, solubility etc. 
but also by measurement of their catalytic activity as the most characteristic property of 
enzyme molecules. For such studies, it is important to use the enzyme with known structure 
and reaction mechanism, available in sufficient purity, and measurable by simple assay 
method. Aminotransferases belong to such enzymes. That is the reason why research 
activities of our laboratory devote to inhibition of aminotransferases by low-molecular 
compounds for many years (e.g. Dršata & Veselá, 1984; Netopilová et al., 1991; Netopilová 
et al., 2001). Our studies of aminotransferase glycation belong to the efforts made also by 
several other research groups (see e.g. Okada & Ayabe, 1997; Fitzgerald et al., 2000; Seidler 
& Kowalewski 2003; Hobart et al., 2004). 
1.1 Aminotransferases 
Aspartate aminotransferase (AST, EC 2.6.1.1) and alanine aminotransferase (ALT, EC 
2.6.1.2), enzymes frequently assessed in clinical laboratories, catalyse reversible transfer of 
α-amino group from amino acids aspartate and alanine to the acceptor 2-oxoglutarate, 
respectively. The resulting products are oxaloacetate, pyruvate and glutamate. In 
metabolism, AST activity mediates the connection between the metabolism of amino acids 
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and saccharides and participates in the transportation of reduced equivalents across the 
membrane of mitochondria as a part of the malate–aspartate shuttle. The catalytic activities 
of AST in cells are implemented by two isoenzymes—the cytosolic and the mitochondrial 
one, which differ in primary structure and in some properties (Yagi et al., 1985; Metzler et 
al., 1979). 
Porcine heart cytosolic AST, which was used in further described experiments of our 
research group, is a homodimer with molecular mass of about 93,150 Da. Both subunits are 
composed of 412 amino acid residues. This dimer contains 38 lysine and 52 arginine 
residues with six Lys–Arg and four Arg–Lys sequence pairs (Seidler & Kowalewski, 2003). 
Presence of these amino acid residues makes glycation of aminotransferases in vitro as well 
as in vivo possible. The Lys258 binding coenzyme PLP could be one of the possible targets of 
glycating agents as can be seen from the loss of enzymatic activity due to the effect of 
methylglyoxal as well as other glycating agents (e.g. Boušová et al., 2009; Seidler & 
Kowalewski, 2003). 
Aminotransferases are characterised by the presence of coenzyme pyridoxal-5’-phosphate 
(PLP) and its direct participation in catalysis. The protein part of aminotransferase 
molecules consists of two identical, non-covalently bound subunits, which are composed of 
one small and one large domain. PLP coenzyme forms a Schiff base with ε-amino group of 
lysine residue (Lys313 in ALT and Lys258 in AST) located in an active site of the larger 
domain of each subunit (Kirsch et al., 1984). The PLP form of AST shows, depending on pH, 
a major absorption peak at 360 nm (an active, unprotonized form of the coenzyme, 
prevailing at lower pH values), and/or a peak at 430 nm (an inactive, protonized form, 
increasing at lower pH values) (Kirsch et al., 1984). After a reaction with L-aspartate during 
the first part of a ping-pong transaminating reaction, the pyridoxamine-5’-phosphate (PMP) 
form of the coenzyme appears and the original absorption maximum shifts to 325–330 nm 
(Fig. 1A). While free PLP or PMP are not optically active substances, the coenzyme bound in 
the active site of AST shows circular dichroism (CD) spectra in the range of 300–500 nm, 
which are similar to absorption spectra (Fig. 1C). The CD effect is caused by the change in 
the electronic configuration of the molecule (Kelly & Price, 2000). Circular dichroism clears 
away absorption characteristics of optically inactive components, which facilitates 
identification of the specific coenzyme signal and its changes (Dršata et al., 2005). This 
method is also a powerful tool for characterizing secondary (190-240 nm, chromophore is 
peptide bond) and tertiary (250-320 nm, chromophores are aromatic amino acids and 
disulfide bonds) structures of studied proteins as well as determining whether the protein is 
folded (Kelly & Price, 2000).  
1.2 Non-enzymatic glycation of proteins 
Non-enzymatic glycation, also called Maillard reaction, was first described in 1912 by Louis 
Camille Maillard (Monnier, 1989). This non-enzymatic browning process had been first 
extensively studied by food chemists and later has become the center of attention of 
geological or agricultural sciences. Much later it was recognized that the process is 
important for medical science (Monnier, 1989; Singh et al., 2001). A very common but 
serious human disease is diabetes mellitus,  which in its untreated or unsuccessfully treated 
form is accompanied with development of chronic complications due to increased intra- and  
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Fig. 1. Characteristic UV-VIS absorption and CD spectra of AST (panel A and C) and of the 
free coenzyme (panel B). (A) UV-VIS spectra of AST (1 mg/mL; 0.1 M sodium phosphate 
buffer, pH 7.4) alone or in the presence of L-Asp (1 mM), (B) UV-VIS spectra of free PLP (0.1 
mM) and PMP (0.1 mM) in sodium phosphate buffer (0.1 M; pH 7.4) were recorded using a 
diode array spectrophotometer HP 8453 (Hewlett Packard, USA) in a 0.5 cm quartz cuvette 
against sodium phosphate buffer (0.1 M; pH 7.4). (C) CD spectra of AST (1 mg/mL; 0.1 M 
sodium phosphate buffer, pH 7.4) alone or in the presence of L-Asp (1 mM) were recorded 
using a dichrograph CD6 (Jobin Yvon, France) in a 0.5 cm quartz cuvette against sodium 
phosphate buffer (0.1 M; pH 7.4). For further details on experimental work see  
(Dršata et al., 2005) 
extracellular concentration of glucose including  a hallmark of the disease - hyperglycemia. 
There is increasing evidence that Maillard reaction plays an important role in the onset and 
progression of some other diseases, such as atherosclerosis and Alzheimer’s disease 
(Nursten, 2005; Yegin et al., 1995). Plenty of studies have been devoted to investigation of 
protein structural and functional changes caused by glycation process (e.g. Jabeen & 
Saleemuddin, 2006; Seidler & Seibel, 2000; Yan & Harding 1997, 2006; Zeng et al., 2006; Zhao 
et al., 2000). 
1.2.1 Formation of advanced glycation end-products 
The early stage of the Maillard reaction is initiated by non-enzymatic condensation of a 
reducing sugar or a certain related compound (e.g. ascorbate) with a free amino group of a 
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protein, a lipid or a nucleic acid. In the case of glucose, the reaction first leads to the formation 
of acid-labile Schiff base, which undergoes a rearrangement to a relatively stable Amadori 
product, e.g. fructosamine. Only a small portion of these Amadori-adducts experiences further 
rearrangements leading to an irreversible formation of advanced glycation end-products 
(AGEs) (Monnier, 1989). The reaction with fructose proceeds in a similar way, but it is called 
Heyns rearrangement and two separate Heyns products are generated (Suarez et al., 1989). 
The formation of Schiff base proceeds in the range of hours and it is fully reversible, while 
Amadori rearrangement takes days and is reversible only to a certain extent. 
In the intermediate stage, Amadori product subsequently degrades and various reactive 
intermediates are formed. These products are known as α-dicarbonyls or α-oxoaldehydes 
and are represented by products like methylglyoxal (MGO), 3-deoxyglucosone (3-DG), and 
glyoxal (GO). Also a Schiff base is a potential source of reactive α-dicarbonyls, because it can 
be fragmented to MGO and GO. These dicarbonyls possess higher reactivity towards 
proteins than the parent monosaccharide. They are capable of forming various cross-links as 
well as chromo/fluorophoric adducts called AGEs, upon reaction with proteins (Schalkwijk 
et al., 2004; Wolff et al., 1991). Both MGO and 3-DG form adducts with proteins and nucleic 
acids up to 10,000 times more readily than glucose (Beisswenger et al., 2003). The 
accumulation of α-dicarbonyl compounds is termed carbonyl stress (Miyata et al., 1999). The 
other process proceeding during the intermediate stage of glycation is metal catalyzed 
autoxidation of glucose, in which the carbonyl compounds (arabinose and glyoxal), H2O2 
and free radicals are formed (Hunt et al., 1988; Wolff & Dean, 1987). The generated free 
radicals initiate further oxidative steps. The glycation process accompanied by oxidation 
steps is called glycoxidation (Baynes, 1991). Various pathways incorporated in the formation 
of AGEs are shown in Fig. 2. 
The advanced glycation end-products are formed during the late stage of glycation over a 
period of weeks, thereby affecting predominantly long-lived proteins, such as collagen and 
lens crystallins. They represent a heterogeneous group of compounds rising from different 
precursors. The chemical structures of AGEs have not been fully described yet. These 
compounds are formed either by oxidative pathway (pentosidine and CML) or by non-
oxidative pathway (pyrraline, DOLD, GOLD, MOLD, and CEL) as can be seen in Fig. 2. 
Proteins modified by advanced glycation are characterized by a much higher molecular 
weight than the original protein, a yellow-brown pigmentation, a typical fluorescent spectra 
(λex/λem: 370/440 nm), an ability to form various cross-links, and by their biological half-life, 
which is comparable to the half-lives of parent proteins (Lapolla et al., 2005; Singh et al., 2001). 
Glucose is the least reactive of the common sugars and that is probably the reason for its 
evolutionary selection as the principal sugar in vivo (Bunn et al., 1978). Because of its low 
reactivity towards proteins, AGEs have been thought to form only at long-lived extracellular 
proteins, such as collagen, crystallines, and myelin. Recently also rapid intracellular AGE 
formation by various intracellular sugars (e.g. fructose, ribose, glyceraldehyde, 
dihydroxyacetone phosphate, glyceraldehyde-3-phosphate, glyoxal, methylglyoxal, and 3-
deoxyglucosone) in vivo has been described. The rate of glycation is directly proportional to 
the percentage of sugar in the open-chain form and the rate for fructose (0.7% open-chain) is 
7.5-fold faster than that of glucose (0.002% open-chain). More strikingly, the glycolytic 
intermediate glyceraldehyde-3-phosphate (100% open-chain) forms 200-fold more glycated 
proteins than do equimolar amounts of glucose (Schalkwijk et al., 2004). 
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Fig. 2. Three stages of non-enzymatic glycation reaction. CML, N-ε-(carboxymethyl)lysine; 
GOLD, glyoxal-lysine dimer; CEL, N-ε-(carboxyethyl)lysine; MOLD, methylglyoxal-lysine 
dimer; 3-DG, 3-deoxyglucosone; DOLD, deoxyglucosone-lysine dimer 
1.2.2 Structure of AGEs 
The advanced glycation end-products found under physiological conditions can be 
classified according to their fluorescent properties and their ability to form cross-links. The 
first group is represented by fluorescent AGE cross-links, which are thought to be 
responsible for a major share of the deleterious effects of AGEs in diabetes and aging. 
Fluorescence is a good qualitative indicator used to estimate AGEs formation. Pentosidine, 
crossline, and various vesperlysines are members of this group. However, also non-
fluorescent AGE cross-links are found in vivo. Their isolation and identification is more 
complicated than in the case of fluorescent AGE cross-links. It is thought that they account 
just for 1% of all cross-links rising under physiological conditions. Various imidazolium 
dilysine cross-links (GOLD, MOLD), arginine-lysine cross-links, and glucosepan belong to 
this group. Last but not least, a group of non-cross-linking protein bound AGE structures 
have been identified in vivo. These structures may exert deleterious effects as precursors of 
cross-links or as biological receptor ligands inducing a variety of adverse cellular and tissue 
changes. The well-known members of this group are pyrraline, carboxyalkyllysines (CML, 
CEL), imidazolones, and argpyrimidine (Ulrich & Cerami, 2001). Classification and 
examples of each above mentioned group are shown in Fig. 3. 
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Fig. 3. Classification of AGEs formed under physiological conditions including several 
examples to each group. [Lys] represents a desamino-lysine residue; [Arg] stands for a 
desguanidino-arginine residue; R represents either hydrogen atom (GOLD), methyl group 
(MOLD), 1,2,3-trihydroxypropyl (DOLD) or 2,3,4-trihydroxybutyl group (imidazolone A and B). 
1.2.3 Therapeutic strategies targeting the AGEs 
The therapeutic intervention to the glycation process has followed three main approaches. A 
first approach follows inhibition of RAGE by neutralizing antibodies or suppression of post-
receptor signaling using antioxidants. A second one is inhibition of AGE formation process 
by carbonyl-blocking agents (aminoguanidine) or by antioxidants. The last approach is 
reducing AGE deposition by using cross-link breakers or by enhancing cellular uptake and 
degradation. 
Interactions of AGEs with the receptor for AGEs (RAGE) have been implicated in the 
development of diabetic vascular complications, which cause various disabilities and 
shortened life expectancy, and reduced quality of life in patients with diabetes. These 
undesirable effects can be suppressed by the use of specific antibodies to RAGE, soluble 
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RAGE or by suppression of post-receptor signaling using antioxidants (Hudson et al., 2003; 
Stuchbury & Münch, 2005). The secreted RAGE form, named soluble RAGE (sRAGE), acts 
as a decoy to trap ligands and prevent interaction with cell surface receptors (Bucciarelli et 
al., 2002). Soluble RAGE was shown to have important inhibitory effects in several cell 
culture and transgenic mouse models, in which it prevented or reversed full-length RAGE 
signaling. The administration of sRAGE has been shown to suppress accelerated diabetic 
atherosclerosis (Park et al., 1998). 
Aminoguanidine, also known by its trade name Pimagedine (Alteon Inc.), is a prototype 
therapeutic agent for prevention of the AGEs formation. It is a low-molecular, highly 
nucleophilic hydrazine compound that rapidly reacts with α-dicarbonyl compounds such as 
MGO, GO, and 3-DG to prevent formation of AGE cross-links. The products of the 
scavenging reaction are substituted 3-amino-1,2,4-triazines. Aminoguanidine does not affect 
the formation of the Schiff base and Amadori products (Thornalley et al., 2000). Clinical 
trials of aminoguanidine in overt diabetic nephropathy (ACTION) were performed, but they 
were early terminated due to safety concerns. Reported side effects of aminoguanidine in 
clinical therapy were gastrointestinal disturbance, abnormalities in liver function tests, flu-
like symptoms, and a rare vasculitis (Bolton et al., 2004; Thornalley, 2003). Other 
nucleophilic compounds, which are designed to trap reactive carbonyl intermediates in 
AGE formation, are for example OPB-9195, diaminophenazine, tenilsetam, and 
pyridoxamine (Baynes & Thorpe, 2000; De La Cruz et al., 2004). With regard to the presence 
of free radicals and oxidative steps in the course of glycoxidation, compounds with 
antioxidant effect such as α-lipoic acid, α-tocopherol, ascorbic acid, and ß-carotene were 
tested. Dipeptide carnosine, pyridoindole derivative stobadine, hypolipidemic drug 
probucol, and mucolytic remedy N-acetylcysteine are just a few more examples of the 
compounds with described antioxidant properties, which were tested in order to estimate 
their potential protective effect in the process of glycation. Also some antioxidant enzymes 
such as superoxide dismutase, catalase, and selenium-dependent glutathione peroxidase 
may protect proteins against impairment caused by non-enzymatic glycation (De La Cruz et 
al., 2004; Kyselova et al., 2004). 
Aminoguanidine and other compounds mentioned before can inhibit the formation of new 
AGE cross-links, but they are not able to cleave those already formed. Vasan et al. (1996) 
reported the first of cross-link breakers, phenyl thiazolium bromide (PTB). This anti-AGE 
agent chemically breaks α-dicarbonyl compounds by cleaving the carbon-carbon bond 
between the carbonyls. Under physiological conditions, PTB is not stable and therefore its 
analogs were tested and alagebrium chloride (ALT-711), a highly potent cross-link breaker 
with higher stability, has been discovered. This compound successfully completed 
preclinical studies and Phase II clinical study on healthy volunteers (Yamagishi et al., 2008). 
Unfortunately, the specific types of AGEs affected by alagebrium are more important in rats 
than humans; hence the promising results in animals were never repeated in human studies. 
Randomized Phase II clinical trial (BENEFICIAL) in patients with chronic heart failure 
(Willemsen et al., 2010) has been terminated early due to financial constraints.  
The objective of current study was to evaluate potential antiglycation activity of two 
mitochondrial antioxidants, α-phenyl N-tert-butyl nitrone (PBN) and N-tert-butyl 
hydroxylamine (NtBHA). PBN is a nitrone that traps free radicals and protects against 
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damage in different models such as inflammation, ischemia reperfusion, and aging. Its 
decomposition product NtBHA mimics PBN and is much more effective in delaying 
senescence of human lung fibroblasts IMR90 (Atamna et al., 2000). NtBHA appears to act on 
mitochondria to delay alterations in function (Atamna et al., 2001). Supplementation with 
NtBHA improved the respiratory control ratio of mitochondria from liver of old rats 
(Atamna et al., 2001). 
1.3 Summary of existing results 
Our laboratory deals with research of the protein glycation in vitro for many years. 
Aminotransferases were chosen as suitable model proteins, because they are commercially 
available in a highly purified and stable form, their structures and mechanism of catalysis 
are well known, and at least two simple methods for their enzyme activity assessment are in 
use. This subchapter summarizes results, which have been obtained by our research group 
up to now. 
In our laboratory, we found decrease in alanine aminotransferase (ALT, EC 2.6.1.2) activities 
in the presence of several reducing monosaccharides in vitro. The decrease in the catalytic 
activity of ALT from porcine heart after 20 days of incubation with D-glucose, D-fructose, D-
ribose or D,L-glyceraldehyde varied and was dependent on the nature of glycating agent 
(the percentage of sugar present in open-chain form). The dependence of enzyme 
inactivation on the presence of these sugars and time of incubation is presented in Fig. 4 
(Beránek et al., 2001). As was described earlier, the rate of glycation is directly proportional 
to the percentage of sugar in the open chain form and the rate for fructose (0.7% open-chain) 
is 7.5-fold faster than that of glucose (0.002% open-chain). More strikingly, the glycolytic 
intermediate glyceraldehyde 3-phosphate (100% open-chain) forms 200-fold more glycated 
proteins than do equimolar amounts of glucose (Schalkwijk et al., 2004).  
 
Fig. 4. An effect of glycation on ALT activity. ALT was incubated with 50 mM sugars in 
sodium phosphate buffer (0.1 M, pH 7.4) at 25 °C. Aliquots of samples were taken at days 0, 
2, 6, 9, 13, 20 and remaining enzyme activities in samples were determined. Activity was 
expressed as a percentage of the activity of the control sample (without sugars). ● ALT with 
D-glucose;  ALT with D-ribose; ALT with D-fructose; ■ ALT with D,L-glyceraldehyde 
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Fructose, ribose and glyceraldehyde have been found more potent glycating agents than 
glucose. The strongest glycation effect was exerted by D,L-glyceraldehyde. Complete 
enzyme inhibition was reached after 6 days but most enzymatic activity (about 75%) was 
reduced in the course of the first 2 days of incubation. Moreover, a decrease in ALT activity 
to 88% of the relevant control was apparent at the zero-time determination of the enzymatic 
activity in the glyceraldehyde sample. Similar results were obtained with AST (Beránek et 
al., 2002). These data are presented in Fig. 5.  
 
 
 
Fig. 5. Inhibitory effect of glycation on the catalytic activity of aminotransferases incubated 
in sodium phosphate buffer (50 mM, pH 7.4) at 4 °C (―――), 25 °C (––––) and 37 °C (–·–·–) for 
up to 56 days. The values show residual catalytic activities of the enzymes related to the 
appropriate control. (A) ALT incubated with 50 mM D-fructose; (B) AST with 50 mM D-
fructose; (C) ALT with 500 mM D-fructose; (D) AST with 500 mM D-fructose. 
In our further experiments, aspartate aminotransferase (AST, EC 2.6.1.1) has been chosen as 
a model protein due to its relative stability during in vitro incubation and availability of the 
enzyme preparations of high purity (for further experimental details see Dršata et al., 2005).  
The purity of the enzyme preparation was crucial for experiments with prolonged 
incubation. While AST activity of the rat liver 20 000 x g supernatant was very unstable in 
vitro and declined rapidly independently of presence or absence of sugar during incubation 
even at 25 °C, the purified preparation enabled experiments using incubation for many days 
(Tupcová, 1996). Data are presented in Fig. 6. 
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Fig. 6. Comparison of stability of AST in rat liver supernatant and in purified preparation 
from pig heart during in vitro incubation at 25 °C. The incubation mixture was diluted 
before the assay in order to obtain activities within the analytical range of the method. 
Values are mean ± S.D. of three independent samples. Each sample was measured 
three-times and the mean was used to calculate the value presented. 
Moreover, glycation of AST was accompanied by a decrease in its catalytic activity in 
dependence on the concentration and activity of the glycating agent, while the concentration 
effect was not clearly demonstrated in case of ALT (Dršata et al., 2002). The effect of substrates 
(2-oxoglutarate and L-aspartate) on AST stability and on glycation process was assessed as 
well. There was no effect of 2-oxoglutarate on the control AST activity throughout the 
experiment, which demonstrated a high stability of the pyridoxal form both in the presence 
and absence of this substrate. On the other hand, the presence of 25 mM L-aspartate (inducing 
the pyridoxamine form of the enzyme) caused a rapid decrease in AST activity even in the 
control reaction (Dršata et al., 2002). The results of AST incubation with D-ribose and D-
fructose in presence of 0.5 mM 2-oxoglutarate suggested that AST glycation could be partly 
prevented by this substrate. This finding supports the idea that Lys258 in the active center of 
AST is involved in glycation of the free enzyme (Fig. 7, taken from Dršata et al., 2002). 
The in vitro model of protein glycation (AST) by D-fructose has been then established and 
experimentally used.  (Boušová et al., 2005a). As mentioned above, attempts have been 
made by researchers to investigate various chemical compounds as potential antiglycating 
agents. With this model, influence of potential antiglycating compounds with antioxidant 
activities was investigated. In an attempt to reduce glycoxidation process and formation of 
AGEs, influence of endogenous antioxidant uric acid (0.2-1.2 mM) on glycoxidation process 
of AST by 50 mM and 500 mM D-fructose in vitro was studied. Uric acid at 1.2 mM 
concentration reduced AST activity decrease caused by incubation of the enzyme with 50 
mM sugar up to 25 days at 37 °C (Fig. 8), as well as formation of total fluorescent AGE 
products (Fig. 9). The results obtained supported the hypothesis that uric acid has beneficial 
effects in controlling protein glycoxidation (Fig. 8 and 9). 
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Fig. 7. Influence of substrates on AST activity during glycation by D-ribose in vitro. 
Concentration of the enzyme (purified Serva preparation) in the incubation mixture: 0.413 
mg/ml, final catalytic concentration in the mixture 7.83 µkat/mg. Values are mean ± S.D. of 
6 (control) or 3 (with D-ribose) independent samples. Each sample was measured three-
times and the mean was used to calculate the value presented.  
L-Asp = L-aspartate; 2-OG = 2-oxoglutarate 
 
Fig. 8. Effect of glycation on AST activity and intervention of uric acid (UA) in the process. 
AST (1.33 mg/ml) was incubated with and without fructose (Frc) in 0.1 mM phosphate 
buffer, pH 7.4 at 37 °C in the presence or absence of 1.2 mM uric acid. AST activity was 
expressed as percentage of that of control sample (without sugar), which was considered as 
100% ± S.D. (%) at every interval. Each point represents an average of three experiments in 
interval 0-12 days, and an average of two experiments on the 15th and 21st day. Each 
experiment was performed in triplicate (*data with P<0.05, Student’s t-test). 
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Fig. 9. Formation of fluorescent products of glycation under the conditions of long lasting 
incubation. AST (1.33 mg/ml) was incubated with or without D-fructose in sodium 
phosphate buffer (0.1 M, pH 7.4) at 37 °C in the presence or absence of 1.2 mM uric acid 
up to 25 days. Aliquots of samples were taken on days 0, 1, 3, 5, 25, and arising 
fluorescent AGE products in samples were determined at specific wavelengths of 
excitation and emission (λex/λem) corresponding to total AGEs (370/440 nm). Data of 
relative fluorescence were expressed in arbitrary units per mg of protein ± S.D., with 1 AU 
corresponding to the fluorescence of BSA 1.0 mg/ml. Every point in days 0 and 5 
represents an average of four experiments (10 samples), in days 1 and 3 an average of 
three experiments for mixtures with 50 mM fructose (7 samples) and of two experiments 
for mixtures with 500 mM fructose (4 samples), and in day 25 an average of three 
experiments (7 samples), (*data with P<0.05, Student’s t-test). 
Also  further studies of our research group have been pointed at possible protective activity 
of selected natural compounds (e.g. hydroxycinnamic acids, flavonoids, arbutin, 
hydroxycitric acid) on AST glycation by fructose. The results have shown that these 
compounds can exert also negative effects on enzyme activity but some of them have been 
able to slow down the course of AST modification by glycating agent. The compound with 
overall positive activity has been hydroxycitric acid (Fig. 10), which is major active 
component in the fruit rinds of certain species of the plant Garcinia. The effect of this 
compound was concentration-depended and its positive activity was most pronounced at 
2.5 mM concentration. On the other hand, flavonoid baicalin (Fig. 11) and its aglycone 
baicalein rapidly decreased the in vitro activity of the enzyme in all concentrations used (0.5–
3 mM), and no beneficial effects of these compounds on glycation of the enzyme by fructose 
were found (Boušová et al., 2005b).  
www.intechopen.com
 
Non-Enzymatic Glycation of Aminotransferases and the Possibilities of Its Modulation 
 
97 
 
Fig. 10. The effect of hydroxycitric acid (HCA) on the glycation of AST by fructose in vitro. 
Concentration of AST in incubation mixtures was 1.33 mg/ml. AST was incubated with or 
without D-fructose 50 mM in sodium phosphate buffer (0.1 M, pH 7.4, 0.05% sodium azide) 
at 37 °C in the presence or absence of HCA up to 21 days. The samples were diluted before 
the assay to fit to the analytical range of the method. Values are expressed as a percentage of 
the activity of respective control (AST) ± S.D. of six independent samples (*data with P<0.05, 
Student’s t-test).  AST;  AST + Frc 50 mM; ▲ AST + Frc + HCA 2.5 mM; ∆ AST + Frc + 
HCA 5.0 mM;  AST + Frc + HCA 7.5 mM; o AST + Frc + HCA 10.0 mM.  
 
Fig. 11. Direct effect of baicalin on the AST activity in vitro. Concentration of AST in 
incubation mixtures was 1.33 mg/ml in 0.1M sodium phosphate buffer (pH 7.4; 0.05% 
sodium azide). Incubation at 37 °C. The samples were diluted before the assay to fit to the 
analytical range of the method. Values are expressed as mean ± S.D. of six (control and AST 
+ Frc 50 mM) or three (with baicalin) independent samples (*data with P<0.05, Student’s t-
test).  AST;  AST + Frc 50 mM; ▲ AST + baicalin 0.5 mM; ∆ AST + baicalin 1.0 mM;  AST 
+ baicalin 1.5 mM; o AST + baicalin 3.0 mM.  
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Following experiments were conducted using methylglyoxal (MGO) as a glycating agent, 
because this compound has higher glycating potential than reducing monosaccharides and 
the incubation period has been shortened to one week only. Changes in the catalytic activity 
of AST caused by MGO were observable even after 120 min of incubation at 37 °C. 
Antiglycating activity of hydroxycitric (Fig. 12) and uric acid has been studied in this 
modified model (Boušová et al., 2009). 
 
 
 
 
 
 
 
 
Fig. 12. Effect of glycation on AST activity and its intervention by hydroxycitric acid. AST (5 
µg/ml) was incubated with or without methylglyoxal (0.5 mM) in 0.1 M sodium phosphate 
buffer (pH 7.4) at 37 °C in the presence or absence of hydroxycitric acid (1.0 and 2.5 mM). 
Catalytic activity of AST was expressed as percentage of each sample activity at the time 0, 
which was 100% ± S.D. (%). Every point represents an average of two independent 
experiments, in which assays were performed in triplicates († data with P<0.05 and *data 
with P<0.01, Student’s t-test). 
2. Methods 
Following parameters have been assessed: enzyme activity, fluorescence (total AGEs and 
argpyrimidine), amount of primary amino groups, molecular charge of AST (using native 
polyacrylamide gel electrophoresis), and protein cross-linking and aggregation (using 
polyacrylamide gel electrophoresis under reducing conditions with subsequent western 
blotting). Structures of all tested compounds are shown in Fig. 13. 
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Fig. 13. Structures of tested compounds 
2.1 Sample preparation and incubation 
The enzyme suspension was centrifuged at 5000 rpm at 4 °C for 20 minutes, the supernatant 
was removed, and protein pellet was reconstituted in 0.1 M sodium phosphate buffer (pH 
7.4, 0.05% sodium azide) and the stock solution of 1.0 mg/ml was prepared. This stock 
solution was used for the preparation of four different types of incubation mixtures: (a) 
control samples (with buffer only), (b) methylglyoxal-modified samples (with MGO in a 
final concentration of 0.5 mM), (c) direct protein-antioxidant interaction samples (with 
individual antioxidants in a final concentration 0.5-10 mM), (d) antiglycation samples (with 
individual antioxidants in a final concentration of 0.5-10 mM and MGO in a final 
concentration 0.5 mM). The inhibitory effect of α-phenyl N-tert-butyl nitrone and N-tert-
butyl hydroxylamine on protein glycation was compared to the effect of aminoguanidine 
(AG) in a concentration of 1.0 mM and Trolox in a concentration of 2.5 mM. The final 
concentrations of the enzyme were 5 µg/ml for catalytic activity assessment and 0.5 mg/ml 
for electrophoresis, amine content and fluorescence measurements. All incubation mixtures 
were incubated in the dark at 37 °C for up to 14 days. The low-molecular compounds were 
removed using Amicon centrifugal filtration device with 0.1 M sodium phosphate buffer 
(pH 7.4), protein content was measured using Bradford assay, and adjusted to the 
concentration 0.5 mg/ml. Aliquots were stored frozen at -20 °C until analysis. All samples 
were assessed in triplicates and experiments were repeated twice if not stated otherwise. 
2.2 Enzyme assay 
Catalytic activity of AST was assessed spectrophotometrically using kinetic UV method 
with addition of PLP (Bergmeyer et al., 1986). Sample aliquots were diluted by 0.1 M 
sodium phosphate buffer (pH 7.4) to obtain enzyme activities within the analytical range of 
the method used. Sampling and measuring was carried out at 37 °C in the intervals 0, 120, 
and 240 minutes using Helios ß spectrophotometer. Absorbance changes at 340 nm were 
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used to calculate enzyme activities. All results of enzyme assays were expressed in µkat/l 
and usually recalculated as activities relative to those of the value of individual sample at 
time 0. 
2.3 Fluorescence measurements 
Formation of fluorescent AGEs and argpyrimidine were measured using the method of Wu 
& Yen (2005) with some modifications. Briefly, samples were incubated for 7 days at 37 °C. 
The aliquots were taken away at time 0, 3 and 7 days and stored frozen at -20 °C. Aliquots of 
time 0 were used as unincubated blanks. Fluorescence of samples was measured at 
excitation and emission wavelengths of 330 nm/410 nm (fluorescent AGEs) and 320 nm/380 
nm (argpyrimidine) against corresponding blanks in 96-well-plate by microplate reader 
(Tecan Infinity M200) using 0.1 mg of protein per well. The percentage inhibition of AGEs 
and argpyrimidine formation were calculated according to following formula: % inhibition 
= [1 - (fluorescence of test group/fluorescence of glycated control)] x 100%. 
2.4 Determination of primary amino groups 
Amine content, which is a measure of protein glycation, was estimated spectrophotometrically 
with trinitrobenzenesulfonic acid (Steinbrecher, 1987) using ß-alanine as the standard. Sample 
containing 50 µg of AST was incubated with 0.1% trinitrobenzenesulfonic acid in alkaline 
conditions for 2 h at 37 °C. The reaction was stopped by acidification (1 M HCl) and addition 
of 10% sodium dodecyl sulfate. The absorbance of trinitrophenyl-amino acid complex was 
measured at 340 nm. The standard curve was linear in the range 5–100 nmol of NH2. 
2.5 Effect of glycation on molecular charge of AST 
Native polyacrylamide gel electrophoresis (PAGE) was used to investigate the changes in 
the molecular charge of AST due to glycation. Electrophoresis was performed in 
discontinuous system with 4% stacking gel and 7.5% separating non-denaturating gel 
(Ornstein, 1964; Davies, 1964). All lanes were loaded with 9 µg of protein. Electrophoresis 
was performed at 30 mA for 2 hours using Mini ProteanIII apparatus. The gel was then 
stained by colloidal Coomassie Blue G250, scanned, and relative migration distances were 
calculated from Rf using Quantity One software. Electrophoretic mobilities were expressed 
as a rise in percentage mobility compared to the native enzyme (control). 
2.6 SDS-PAGE and western blotting 
Protein cross-linking and aggregation were assessed using a sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS–PAGE) on Mini ProteanIII apparatus (BioRad). 
SDS-PAGE was performed using discontinuous system with 4% stacking gel and 10% 
separating gel (Laemmli, 1970). Lanes were loaded with 4 µg of protein. Proteins after 
electrophoretic separation were transferred to PVDF membrane (0.2 µm, Bio-Rad) at a 
constant voltage 100 V for 90 minutes (Mini Trans-Blot Electrophoretic Transfer Cell, Bio-
Rad). After blotting, membranes were blocked with 8% non-fat dry milk in Tris buffered 
saline-Tween-20 buffer (TBST) overnight at 4°C, then washed in TBST and reacted with 
primary antibody (dilution 1:1000) for 45 minutes at room temperature. Subsequently, 
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membranes were washed six times with TBST and incubated with secondary antibody for 
45 minutes (dilution 1:1000). The blots were extensively washed in 0.1 M TRIS buffer 
containing 5 mM MgCl2.6H2O (pH 9.5), covered with chemiluminescent substrate DuoLux 
(Vector Laboratories) and incubated for 5 minutes. The membranes were then exposed to X-
ray film (CL-XPosure film, Thermo Fisher Scientific), developed by standard developing 
process, and images were recorded with a GelDoc XR system. The blots were 
densitometrically quantified using Quantity One software. 
2.7 Statistical analysis 
Values of catalytic activity are given as means ± S.D. and mostly expressed in % of the time 0 
of individual samples ± relative S.D. Values of fluorescence (AU) are given as means ± S.D. 
Statistical significance was determined using Student’s t-test and differences were regarded 
as significant when P<0.05 and P<0.01, respectively. 
3. Results and discussion 
The activity of tested compounds was compared to the effect of known carbonyl-blocking 
agent aminoguanidine and to the effect of Trolox (water-soluble derivative of vitamin E), 
which is often used in various methods for assessing antioxidant/antiradical properties of 
potential antioxidants as reference compound. 
3.1 Enzyme assay 
Activity of control sample (AST alone) was stable throughout the experiment. Some of 
tested compounds had a more or less pronounced negative direct effect on enzyme activity, 
which was probably due to a direct interaction of their molecules with the molecule of the 
enzyme. PBN itself had no harmful influence on stability and catalytic activity of AST in the 
concentrations used (Fig. 14B), while NtBHA caused concentration-dependent decrease in 
AST catalytic activity, which was statistically significant at concentrations of NtBHA 1 mM 
and higher (Fig. 14A). Aminoguanidine 1.0 mM caused significant decrease of enzyme 
activity by 21.7% after 240 min of incubation. This inhibitory effect of AG may be explained 
by its binding to PLP coenzyme forming a Schiff base, which disturbs tissue distribution of 
PLP in vivo and decreases its concentration in liver (Okada & Ayabe, 1995; Taguchi et al., 
1998). Trolox 2.5 mM did not influence AST activity. 
Following incubation of enzyme with MGO 0.5 mM, a rapid decline of AST activity was 
observed. The enzymatic activity decreased to 53.1 and 30.1% of control sample after 120 
and 240 min, respectively. In addition, positive antiglycation effects were observed with 
some compounds. NtBHA exerted antiglycation influence only at 5 mM concentration after 
120 and 240 min and at 1 mM concentration after 240 min of incubation (Fig. 15A). Negative 
direct effect of this compound observed at 10 mM concentration probably outweighed its 
positive antiglycation activity. The catalytic activity of AST was by 33.1% and 16.5% higher 
in the presence of PBN 10 mM and 1 mM after 120 min of incubation with MGO compared 
to the activity of sample containing AST + MGO only (Fig. 15B), respectively. PBN 1-10 mM 
protected AST against MGO-induced glycation also after 240 min of incubation, when all 
three concentrations increased activity of AST by 20%. In comparison, aminoguanidine 1.0 
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mM almost completely reversed negative effect of MGO and the AST activity of the sample 
containing AST + MGO + AG was 86.2 and 76.6% of control sample activity after 120 and 
240 min, respectively. The effect of Trolox 2.5 mM was slightly higher than that of NtBHA 5 
mM. The AST activity was by 15.1 and 13.7% higher in the presence of Trolox after 120 and 
240 min, respectively. 
 
Fig. 14. Direct effect of NtBHA (panel A) and PBN (panel B) on AST catalytic activity. AST 
(0.5 µg/ml) was incubated with or without methylglyoxal (0.5 mM) in 0.1 M sodium 
phosphate buffer (pH 7.4) at 37 °C in the presence or absence of NtBHA (1-10 mM) or PBN 
(1-10 mM). Catalytic activity of AST was expressed as percentage of each sample activity at 
the time 0, which was 100% ± S.D. (%). Every point represents an average of eighteen (AST 
and AST + MGO) or six independent samples (*data with P<0.01, Student’s t-test) 
 
Fig. 15. Antiglycating activity of NtBHA (panel A) and PBN (panel B) towards 
methylglyoxal-induced deactivation of AST. AST (0.5 µg/ml) was incubated with or 
without methylglyoxal (0.5 mM) in 0.1 M sodium phosphate buffer (pH 7.4) at 37 °C in the 
presence or absence of NtBHA (1-10 mM) or PBN (1-10 mM). Catalytic activity of AST was 
expressed as percentage of each sample activity at the time 0, which was 100% ± S.D. (%). 
Every point represents an average of eighteen (AST and AST + MGO) or six independent 
samples (*data with P<0.01, Student’s t-test) 
3.2 Fluorescence measurements 
The inhibition of MGO-mediated protein glycation by several antioxidants was determined 
by measuring of AGEs with fluorescent properties. Figure 16B shows formation of 
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argpyrimidine and the effect of NtBHA on this process. Sample containing AST + MGO 
exerted 12.5 times higher fluorescence intensity than the control sample without MGO after 
7 days of incubation. NtBHA caused statistically significant decrease in the formation of 
argpyrimidine during incubation (inhibition by 42.3–83.1%). The most remarkable decline in 
argpyrimidine formation was observed at 10 mM concentration of NtBHA, which exhibited 
inhibition by 83.1%. Effect of PBN on the argpyrimidine formation was less remarkable 
(inhibition by 35.2–55.8%) but still highly significant (Fig. 16A). The influence of AG 1.0 mM 
was well-pronounced (93.2%), while the effect of Trolox 2.5 mM was much weaker (53.2%) 
and comparable to the activity of NtBHA 1 mM and PBN 1-10 mM.  
The effect of NtBHA on the formation of ‘‘non-specific’’ AGE products is presented in Fig. 
16D. Methylglyoxal caused almost 13 fold increase in concentration of AGEs with fluorescent 
properties compared to the control sample (AST alone) after 7 days of incubation. Positive 
effect of NtBHA reached almost the same extent as in the case of argpyrimidine formation 
with statistically significant inhibition of glycation (34.3–76.6%). Little bit lower rate of 
inhibition (8.9–48.2%) was obtained also with PBN (Fig. 16C). Aminoguanidine and Trolox 
showed 88.7 and 44.4% suppressing effect on AGEs generation, respectively. 
As for fluorescence measurement, control sample showed stable but not negligible 
fluorescence, since the start of the experiment. Most of this fluorescence is probably 
constituted by general fluorescence properties of this protein. Presence of pyridoxal-5’-
phosphate coenzyme in the molecule of AST also contributes to basal fluorescence of the 
enzyme. Results of fluorescence measurements clearly show an inhibiting effect of NtBHA 
and PBN on the formation of AGE products. NtBHA was also quite effective in the 
inhibition of argpyrimidine generation. Apart from these findings, the use of fluorescence 
method for evaluation of protein glycation is limited by its imprecision. The measurement of 
some well-identified AGEs (e.g., pentosidine and carboxymethyllysine) by techniques as 
HPLC or ELISA could give more precise information on this matter (Boušová et al., 2009). 
3.3 Determination of primary amino groups 
Following incubation of AST with methylglyoxal, there was a decrease in amine content 
compared to control (Table 1). Unmodified AST exhibited 25.2 ± 0.4 nmol NH2/mol AST 
versus 13.9 ± 1.1 nmol NH2/mol AST for sample containing AST + MGO (P<0.001, using 
Student’s t-test). This difference represents a 45% decrease in amine content due to chemical 
modification of the primary amines (α-amino group of N-terminal amino acids and ε-amino 
group of Lys residues). Native AST in the dimer form contains 40 primary amines (38 Lys 
residues and 2 N-terminal amino acids), suggesting that approximately 18 amines were 
modified by methylglyoxal. Modification of primary amino group of Lys258 in AST 
molecule by MGO may be also responsible for the loss of its catalytic activity, because this 
Lys residue binds coenzyme PLP in the active centre of AST and thus directly participates in 
the enzymatic catalysis. 
PBN as well as NtBHA significantly protected AST against the loss of primary amino groups 
induced by MGO. Their effect was concentration-dependent and more pronounced in the 
case of NtBHA. Sample containing AST + MGO + NtBHA 10 mM exhibited 21.8 ± 0.7 nmol 
NH2/mol AST (P<0.001, using Student’s t-test) suggesting that about 5 amines were 
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modified by MGO. In the sample containing AST + MGO + PBN 10 mM was found 19.8 ± 
1.2 nmol NH2/mol AST (P<0.001, using Student’s t-test), which means that approximately 9 
amines were lost. This result is comparable to the effect of NtBHA at 1 mM concentration. 
Moreover, AG 1 mM exerted the same effect as NtBHA 10 mM. In the sample containing 
AST + MGO + AG was detected 22.0 ± 0.4 nmol NH2/mol AST suggesting that 5 amines 
was lost in its presence. 
 
Fig. 16. Formation of argpyrimidine (panel A and B) and fluorescent AGEs (panel C and D). 
AST (0.5 mg/ml) was incubated with or without methylglyoxal (0.5 mM) in 0.1 M sodium 
phosphate buffer (pH 7.4) at 37 °C in the presence or absence of PBN (0.5-10 mM), NtBHA 
(0.5–10 mM), aminoguanidine (1 mM) or Trolox (2.5 mM) for 7 days. Aliquots of samples 
were taken on days 0 and 7 and stored frozen at -20 °C. Fluorescence of samples was 
measured at specific excitation and emission wavelengths (λex/λem) corresponding to 
argpyrimidine (335/385 nm) and AGEs (330/410 nm) versus the unincubated blanks. Data 
of fluorescence were expressed in relative fluorescence units ± S.D. Every point represents 
an average of two independent experiments (6 samples). Groups with different letters are 
significantly different (P<0.01, Student’s t-test). 
To determine whether the changes in fluorescence of argpyrimidine observed in the samples 
containing various concentrations of NtBHA (0.5–10 mM) and MGO 0.5 mM correlated with 
the loss of primary amino groups in these samples, the fluorescence intensity was plotted as 
a function of amine content (data not shown). The decrease in fluorescence emission 
(λex/λem = 320/380 nm) varied directly with the loss of primary amino groups (r = 0.963, 
P<0.019). Changes in fluorescence of argpyrimidine in these samples also correlated well 
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with the formation of fluorescent AGEs (r = 0.991, P<0.005). In addition, the amine content 
measured in samples containing AST + MGO + NtBHA (0.5-10 mM) was plotted as a 
function of AGEs fluorescence, indicating that MGO-induced formation of AGEs was 
directly proportional to an irreversible loss of primary amino groups in AST molecule (r = 
0.946, P<0.027). Similar results were obtained also in samples containing AST + MGO + PBN 
(0.5-10 mM). 
 
Sample Amine content Number of primary NH2 
(nmol NH2/mol AST) remaining modified 
AST 25.2 ± 0.4a 40 0 
AST + MGO 0.5 mM 13.9 ± 1.1b 22 18 
AST + MGO + PBN 0.5 mM 17.9 ± 0.9c 28 12 
AST + MGO + PBN 1 mM 18.2 ± 1.1cd 29 11 
AST + MGO + PBN 5 mM 18.6 ± 1.7cd 30 10 
AST + MGO + PBN 10 mM 19.8 ± 1.2d 31 9 
AST + MGO + NtBHA 0.5 mM 17.3 ± 0.4c 27 13 
AST + MGO + NtBHA 1 mM 19.5 ± 0.4d 31 9 
AST + MGO + NtBHA 5 mM 20.8 ± 0.8de 32 8 
AST + MGO + NtBHA 10 mM 21.8 ± 0.7ef 35 5 
AST + MGO + AG 1 mM 22.0 ± 0.4f 35 5 
a,b,c,d,e,f Groups with different letters vary significantly (P<0.05, Student’s t-test) 
Table 1. Effect of PBN, NtBHA and AG on the changes in AST primary amine content 
induced by MGO 0.5 mM 
3.4 Effect of glycation on molecular charge of AST 
Native PAGE was run several times, and the representative native PAGE gel is presented in 
Fig. 17. Mobility of MGO-modified protein to the positive pole significantly increased (by 
41%) after 7 days of incubation compared to the mobility of control sample (AST alone). This 
result indicates the progressive loss of the positive charge in the MGO-modified AST during 
the glycation reaction. NtBHA showed concentration-dependent protective effect against 
changes in AST molecular change induced by MGO, when the relative mobility of sample 
containing AST + MGO + NtBHA 10 mM was increased only by 9.2% compared to the 
mobility of control. The enzyme incubated in the presence of both MGO and PBN showed a 
smaller rise in mobility, up to 21.6% in the case of PBN 10 mM. The effect of this compound 
on the protein electrophoretic mobility ranged from 21.6 to 26.3%. Aminoguanidine 1 mM 
completely reversed effect of MGO and the relative mobility of sample containing AST + 
MGO + AG was only slightly increased (by 0.35%) against the mobility of control, whereas 
Trolox 2.5 mM showed similar effect on molecular charge of AST as PBN, i.e., the mobility 
was increased by 27% compared to control sample (data not shown). These data indicated 
that the molecule of enzyme became more anionic due to glycation and that PBN as well as 
NtBHA had significant inhibitory effect on the middle stage of glycation process. 
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Fig. 17. Protective effect of NtBHA and PBN on changes in molecular change of AST caused 
by MGO-induced glycation. AST (0.5 mg/ml) was incubated with or without MGO (0.5 
mM) and NtBHA (0.5-10 mM) or PBN (0.5-10 mM) in sodium phosphate buffer (0.1 M, pH 
7.4) at 37 °C for 7 days and then subjected to native PAGE. Proteins were visualized by 
Coomassie Blue G250. Gels were scanned and Rf was obtained using Quantity One software 
Methylglyoxal-induced chemical modifications led to a change in molecular charge of AST, 
which became more anionic as revealed by native PAGE. These results indicate the 
progressive loss of the positive charge in the glycation-modified AST molecule, which is 
caused by the irreversible modification of Arg and Lys residues (Kang, 2006; Nagai et al., 
2000) as was confirmed by determination of amine content. Both PBN and NtBHA partially 
protected native AST against glycation by MGO. The antiglycation activity was more 
pronounced in the case of NtBHA mainly at higher concentrations tested. The antiglycation 
activity of NtBHA 10 mM was a little bit lower than that of AG 1 mM. 
3.5 SDS-PAGE and western blotting 
The ability of aggregation and cross-link formation of tested antioxidants was determined 
by SDS-PAGE under denaturing conditions (Fig. 18). MGO readily reacts with lysine and 
arginine residues to produce high molecular weight protein products. Incubation of AST 
with MGO 0.5 mM at 37 °C for 7 days resulted in the formation of protein aggregates with 
molecular weight about 85, 107, and 145 kDa corresponding to protein dimer, trimer, and 
tetramer, respectively. No presence of protein dimer and tetramer, and lower concentration 
of protein trimer were observed in samples containing AST alone (lane 2), AST + NtBHA 10 
mM (lane 7), and AST + AG 1 mM (data not shown). Also lower concentrations of NtBHA 
were able to partially protect formation of protein tetramer, although they had no effect on 
formation of protein dimer and trimer. On the other hand, PBN as well as Trolox were not 
able to prevent formation of protein cross-links and high molecular weight aggregates. 
Additional bands with molecular weight 20–35, 57 and 63 kDa were constituted of several 
contaminating proteins present in commercial preparation (Fig. 18). 
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Western blotting with specific antibody against advanced glycation end products derived 
from MGO (anti-MGO [3C]) was used to confirm formation of protein aggregates as a result 
of MGO activity. The presence of high molecular weight protein cross-links in samples 
containing AST + MGO, AST + MGO + NtBHA, and AST + MGO + PBN was observed (data 
not shown). These protein aggregates had molecular weight about 85, 107, and 145 kDa 
corresponding to AST dimer, trimer, and tetramer, respectively. Quantitative differences 
between bands of samples with and without PBN or Trolox were not observed. These 
compounds are not able to prevent formation of protein cross-links. On the other hand, 
some reduction in the amount of AST tetramer was observed in samples containing NtBHA. 
These results suggest that NtBHA possesses, at least in part, antiglycation properties. 
Nevertheless, aminoguanidine 1 mM completely inhibited formation of protein aggregates, 
since no bands of AST dimer, trimer or tetramer were present. 
The electrophoretic techniques confirmed the results obtained by other methods; i.e., changes 
in protein molecule caused by the presence of methylglyoxal and positive antiglycating effect 
of NtBHA. Methylglyoxal-induced chemical modifications led to a change in molecular charge 
of AST, which became more anionic as revealed by native PAGE. The SDS-PAGE and 
subsequent western blotting clearly showed formation of protein cross-links with higher 
molecular weight than native enzyme. NtBHA partially protected native AST from glycation 
by MGO and also exhibited mild anti-cross-linking activity. 
 
Fig. 18. Formation of protein cross-links on reaction of AST with methylglyoxal. AST  
(0.5 mg/ml) was incubated with or without methylglyoxal (0.5 mM) in sodium phosphate 
buffer (0.1 M, pH 7.4) at 37 °C in the presence or absence of N-tert-butyl hydroxylamine  
(0.5–10 mM) for 7 days and then subjected to SDS-PAGE. Electrophoretic separation was 
performed on 4% stacking and 10% resolving polyacrylamide gels under reducing 
conditions. Bands were visualized with silver staining. Each lane was loaded with 4 µg of 
protein. MM = Mw marker; AST = aspartate aminotransferase; MGO = methylglyoxal; 
NtBHA = N-tert-butyl hydroxylamine 
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Modification of proteins caused by methylglyoxal can be accompanied by formation of free 
radicals. Lee et al. (1998) identified three types of free radical species in samples containing 
methylglyoxal and bovine serum albumin by electron spin resonance spectroscopy. These 
radicals (methylglyoxal dialkylimine radical cation, methylglyoxal radical anion, and 
superoxide anion radical) were formed by direct 1-electron transfer process. Scavenging 
ability of NtBHA and PBN were already described (Lee et al., 2004; Atamna et al., 2001). It 
can be assumed that the positive antiglycation activity of these compounds may be at least 
partly attributed to their scavenging ability.  
4. Conclusion 
- Catalytic activity, which is biologically the most important property of all enzymes, is 
fully dependent on the native structure of the enzyme. Changes in the structure of 
enzymes usually lead to the progressive loss of their catalytic activities. These changes 
may be caused by reversible binding of various low-molecular inhibitors or by 
irreversible modification. Such example of the irreversible change is non-enzymatic 
glycation of proteins by various reducing monosaccharides or reactive α-dicarbonyl 
compounds (e.g., MGO).  
- In our studies, aspartate aminotransferase (AST) was used in glycation studies as model 
protein, which possesses catalytic properties. 
- Catalytic activity of aminotransferases in vitro has been found to be impaired by 
glycating agents. The extent of this effect depends on the activity and concentration of 
the agent, susceptibility of given enzyme to such modification as well as on the 
duration of action (see Fig. 4, Fig. 5 and Fig. 8). 
- Among several glycating agents, effect of fructose is strong enough for investigation of 
changing AST properties during long time of incubation. Nevertheless, methylglyoxal, 
an intermediate of glycation process, is more reactive and permits to investigate the 
process of AST glycation in vitro in shorter course of time. 
- Catalytic activity of AST as the protein function may serve as the most important 
criterion of glycation effect. Beside this, molecular properties of purified AST and 
character of glycoxidation permit using other methods of investigation of molecular 
changes during the process, like fluorescence of advanced glycation end-products, 
decrease in primary amino groups in the protein molecule, and protein cross-linking 
and aggregation. 
- Several approaches of therapeutic intervention to the glycation process have been used 
(e.g., reduction in deposition of already formed AGEs, inhibition of new AGEs 
formation, and inhibition of the receptor for AGE). 
- In our own experiments, compounds with described antioxidant and potential 
antiglycating activities have been studied. Among the compounds studied, 
hydroxycitric acid, uric acid, and two mitochondrial antioxidants α-phenyl N-tert-butyl 
nitrone and N-tert-butyl hydroxylamine had pronounced antiglycating activity against 
protein glycation by methylglyoxal (hydroxycitric acid, PBN and NtBHA) and by 
fructose (hydroxycitric and uric acids). On the other hand, flavonoids baicalin and 
baicalein exerted overall negative influence on the catalytic activity of AST alone and in 
the combination with fructose. Other studied compounds (i.e., ferulic, isoferulic, o-
coumaric, and p-coumaric acids, arbutin and methylarbutin) showed no positive 
antiglycation activity.  
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- The goal of our research group is to participate in the search for compounds with 
potential antiglycating activity with a perspective of their use as remedies against 
diabetic complications. 
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